UW Carbone Cancer Center Director Steps Down, Interim Director Named
After successfully serving 12 years as UW Carbone Cancer Center (UWCCC) director, George Wilding, MD, will step down in September so he can refocus his academic activities as Anderson Professor of Medicine within the Department of Medicine at the University of Wisconsin School of Medicine and Public Health.
“I am proud and honored to have had the privilege of leading the UWCCC for so many years,” said Wilding. “Our patients and their families have greatly benefitted from our research efforts. The more than 2,400 faculty and staff have led the way in cutting-edge advancements in research and clinical care, resulting in improved treatment standards for many patients with many forms of cancer.”
A native of Everett, Massachusetts, Wilding graduated from the University of Massachusetts Medical School, where he also completed his internship and residency in internal medicine. He trained in medical oncology within the Medicine Branch at the National Cancer Institute (NCI). He has a master's degree (pharmacology) from Pennsylvania State University and bachelor's degrees from Tufts University (chemical engineering and biology).
Dr. Wilding has been a UW Carbone Cancer Center member since joining the UW faculty in 1988, when he became chief of oncology at the VA Hospital. He has been fortunate to have more than 25 years of sustained federal peer-reviewed funding for his laboratory and clinical research.
His lab focuses on the role of androgen induced oxidative stress and prostate carcinogenesis, with funding from the NCI, Department of Defense, Prostate Cancer Foundation and industry. Nationally, he will continue to advise a number of cancer centers and serve on the NCI Board of Scientific Counselors.
“During George's tenure as director, the UWCCC has experienced enormous growth in all of its missions. It enjoys a well-deserved outstanding national reputation for excellence, as evidenced by the recent successful renewal of its National Cancer Institute (NCI) core grant,” according to Robert Golden, dean of the UW School of Medicine and Public Health.
Wilding was instrumental in moving the Carbone Cancer Center toward emphasizing multidisciplinary and trans-disciplinary interactions, focusing on the translation of basic research findings to clinical testing and application.
About $250 million has been raised to increase Carbone Cancer Center clinical and research facilities, including the establishment of the Wisconsin Institutes for Medical Research (WIMR). In a few months, Department of Oncology faculty in the McArdle Laboratory for Cancer Research will move into WIMR, fulfilling the vision of Harold Rusch - founder of the McArdle lab and first director of the Wisconsin Clinical Center Center - for an integrated comprehensive cancer center.
Dr. Wilding has spearheaded the recruitment of 30 tenure-track faculty with research space and startup funds and seen the growth of a vigorous outreach network around southern Wisconsin. He has also been instrumental in developing ongoing relationships with more than a dozen cancer centers in Asia on early phase drug development programs.
Howard Bailey Named Interim Director
Howard Bailey, MD, has been named interim UW Carbone Cancer Center director, effective September 1. Dr. Bailey, a professor of medicine at the UW School of Medicine and Public Health, is a medical oncologist who specializes in gynecologic oncology and cancer prevention.
He graduated from the University of North Dakota Medical School and received his internal medicine training at Kalamazoo, Michigan. He underwent fellowship training in medical oncology as well as cancer research at the University of Wisconsin-Madison.
He has been an active cancer clinician and researcher since becoming a faculty member of the University of Wisconsin School of Medicine and Public Health in 1994. He has led the development of three different state- and nation-wide clinical research networks to expand the access of cutting-edge research for patients. Two years ago he was appointed to the national committee which reviews all NCI-designated Cancer Centers.
“Dr. Bailey is a wonderful choice to be named the interim director,” said Wilding. “We have worked closely for several years, and Howard is a strong leader in clinical research and truly focused on patient outcomes.”
In the fall, a national search will begin to find a permanent director.
Date Published: 08/22/2013